2020 Virtual ESMO Review

 

2020 Virtual ESMO Review
L

2020 ESMO Update on Metastatic Pancreatic Cancer: What Does the QoliXane Trial Data Suggest on Time to Deterioration of QoL in Patients Treated With 1L Nab-Paclitaxel?

By 2020 Virtual ESMO Review FEATURING Louise Connell
By 2020 Virtual ESMO Review FEATURING Louise Connell
0 views
November 4, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

05:59
Lilly Medical Affairs

Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …

Feat. J. O’Shaughnessy

Featured Video

06:14
Lilly Medical Affairs

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy
Videos
05:09
2020 Virtual ESMO Review

2020 ESMO Update on R/R DLBCL: Does AUTO3 + Pembro Induce CRs? What …

Feat. J. Amengual
07:49
2020 Virtual ESMO Review

2020 ESMO Update on R/R cHL: How Effective Is Brentuximab Vedotin?

Feat. J. Amengual
06:52
2020 Virtual ESMO Review

2020 ESMO Update on Non-Hodgkin Lymphomas: Does BETi CC-90010 Lead t…

Feat. J. Amengual
07:33
2020 Virtual ESMO Review

2020 ESMO Update on Targeted Therapy in NSCLC: Does ADAURA Trial Sug…

Feat. I. Dagogo-Jack
05:44
2020 Virtual ESMO Review

2020 ESMO Update on Targeted Therapy in NSCLC: Can We Safely Combine…

Feat. I. Dagogo-Jack
06:52
2020 Virtual ESMO Review

2020 ESMO Update on UC: Does 1L Durvalumab +/- Tremelimumab Improve …

Feat. M. Bupathi
08:30
2020 Virtual ESMO Review

2020 ESMO Update on RCC: Is IO + TKI Option Effective in Advanced Di…

Feat. M. Bupathi
07:47
2020 Virtual ESMO Review

2020 ESMO Update on Advanced UC: Does the Addition of Avelumab 1L Ma…

Feat. M. Bupathi
11:16
2020 Virtual ESMO Review

2020 ESMO Update on ALK+ NSCLC: PFS Data With Lorlatinib vs. Crizoti…

Feat. I. Dagogo-Jack
20:42
2020 Virtual ESMO Review

ESMO 2020 Update on mPC: How Beneficial Is Abiraterone+/-Ipatasertib…

Feat. T. Barauskas Dorff
33:00
Total Health

Will COVID-19 Leave Its Mark on Cancer Care?

Feat. G. Lopes
08:53
2020 Virtual ESMO Review

2020 ESMO Updates on Pembrolizumab & Cemiplimab: Can mNSCLC Be C…

Feat. M. Dietrich
06:15
2020 Virtual ESMO Review

2020 ESMO First Results from PIONeeR Project on Biomarkers in Advanc…

Feat. M. Dietrich
09:56
2020 Virtual ESMO Review

2020 ESMO Updates in Lung Cancer: Does 1L Nivolumab–Ipilimumab Boost…

Feat. M. Dietrich
07:30
2020 Virtual ESMO Review

2020 ESMO Update on MBC: Is There OS Benefit to Alpelisib + Fulvestr…

Feat. J. Crozier
10:12
2020 Virtual ESMO Review

2020 ESMO Update on MBC: Does the Addition of Tamoxifen to Abemacicl…

Feat. J. Crozier
08:19
2020 Virtual ESMO Review

2020 ESMO Update on Immune Checkpoint Inhibitors in eTNBC: Does the …

Feat. L. Schwartzberg
06:06
2020 Virtual ESMO Review

2020 ESMO Update on CDK 4/6 in Adjuvant HR+, HER2- EBC: Does the Add…

Feat. L. Schwartzberg
07:46
2020 Virtual ESMO Review

2020 ESMO Update on CDK 4/6 in Adjuvant HR+, HER2- EBC: How Does Two…

Feat. L. Schwartzberg
13:27
2020 Virtual ESMO Review

2020 ESMO Update on mPDAC: Does the Addition of Dual Immune Checkpoi…

Feat. L. Connell
08:07
2020 Virtual ESMO Review

2020 ESMO Update on Metastatic Pancreatic Cancer: What Does the Qoli…

Feat. L. Connell